12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Forxiga dapagliflozin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Dec. 12 to discuss a resubmitted NDA from Bristol-Myers for Forxiga dapagliflozin to treat Type II diabetes....

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >